Aura Biosciences officer awarded stock and options

Kilroy Conor reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Kilroy Conor reported acquisition or exercise transactions in this Form 4 filing.

Aura Biosciences officer Conor Kilroy reported equity awards that increase his holdings. On March 2, 2026, he was granted a stock option for 112,661 shares of common stock at $0.00 per share and an award of 62,339 shares of common stock. The RSU shares vest in four equal annual installments starting January 15, 2027, while the option vests 25% on February 1, 2027 and the remainder in 36 monthly installments, all subject to continued service. After these grants, he directly owns 229,573 common shares and holds options for 112,661 shares.

Insider Trade Summary

Grant/Award: 175,000 shares

Grant/Award 2 txns

Insider Kilroy Conor

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	112,661	$0.00	$0.00
Grant/Award	Common Stock	62,339	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 112,661 contracts (Direct); Common Stock — 229,573 shares (Direct)

Footnotes (2)

1. F1. These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.
2. F2. The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Aura Biosciences (AURA) report for Conor Kilroy?

Aura Biosciences reported that officer Conor Kilroy received two equity awards on March 2, 2026. He was granted a stock option for 112,661 shares at $0.00 and an award of 62,339 common shares as part of his compensation.

How many Aura Biosciences (AURA) stock options did Conor Kilroy receive?

Conor Kilroy received a stock option covering 112,661 shares of Aura Biosciences common stock at an exercise price of $0.00. This option vests over time, beginning on February 1, 2027, subject to his continued service with the company.

What are the vesting terms for Conor Kilroy’s RSU award at Aura Biosciences (AURA)?

The RSU award to Conor Kilroy covers 62,339 common shares and vests in four substantially equal annual installments. Vesting begins on January 15, 2027, and each installment requires his continued service through the applicable vesting date.

What are the vesting terms for Conor Kilroy’s stock option in Aura Biosciences (AURA)?

Kilroy’s stock option for 112,661 shares vests 25% on February 1, 2027. The remaining 75% then vests pro rata in 36 monthly installments, provided he remains in service on each scheduled vesting date.

How many Aura Biosciences (AURA) shares does Conor Kilroy own after these awards?

Following the March 2, 2026 awards, Conor Kilroy directly owns 229,573 shares of Aura Biosciences common stock. In addition, he holds a stock option exercisable for 112,661 shares, which will vest over time according to the disclosed schedule.

Were Conor Kilroy’s Aura Biosciences (AURA) equity awards open-market purchases?

No, the transactions were grants, not open-market purchases. The Form 4 identifies them with code “A” as grant or award acquisitions, with a reported price of $0.00 per share, reflecting equity-based compensation rather than cash purchases.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kilroy Conor

(Last) (First) (Middle)

C/O AURA BIOSCIENCES, INC.

80 GUEST STREET

(Street)

BOSTON MA 02135

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aura Biosciences, Inc. [ AURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		A		62,339(1)	A	$0	229,573	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.14	03/02/2026		A		112,661		(2)	03/02/2036	Common Stock	112,661	$0	112,661	D

Explanation of Responses:

1. These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.

2. The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

Remarks:

Chief Legal Officer and Secretary

	/s/ Conor Kilroy	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.